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Dear Editor,
We would like to discuss the treatment of paroxysmal noc-
turnal hemoglobinuria (PNH) by presenting the fatal out-
come of one of our patients with this disease. A 30-year-old
Caucasian man with a history of auto-immune hepatitis
developed pancytopenia. He had no complaints and did
not take any medication. On physical examination, a pale
man was seen without any other remarkable findings. His
hemoglobin was 8.3 g/dL (13.8–16.9 g/dL), leucocytes 0.30
(neutrophils 0.2)×109/L (3.5–10×109/L), platelet count
16×109/L (150–350×109/L) and reticulocytes 8.4×109/L
(30–95×109/L) without signs of hemolysis. Bone-marrow
biopsy showed reduced cellularity (10 %) without any other
(including cytogenetic) abnormalities. In peripheral blood,
glycosylphosphatidylinositol (PI)-deficient clones were
detected in 34, 27, and 1 % of the granulocyte, monocyte,
and erythroid lineages, respectively. Severe aplastic anemia
(SAA) was diagnosed secondary to PNH. Lacking an HLA-
identical family donor, standard treatment with immunosup-
pression was started: rabbit anti-thymocyte globuline, meth-
ylprednisolone, and cyclosporine. This resulted in a partial
response 3 months later: persistent transfusion-dependent
anemia without signs of intravascular hemolysis, thrombo-
cytopenia, and a normal leucocyte count. An expansion
of the PI-deficient clones up to 86, 86, and 7 % of the
granulocyte, monocyte, and erythroid lineages, respectively
(Fig. 1) was noted.
Three months after initial presentation, he was re-
admitted to hospital because of abdominal pain and bloody
stools. Thrombosis of the superior mesenteric vein was
diagnosed and anticoagulant therapy was instituted with
nadroparin 15,200 IU/day subcutaneously. Eculizumab
treatment was considered, but because of the complete ab-
sence of intravascular hemolysis, the effect of the anticoag-
ulant therapy was awaited. Subsequently, he developed
headache and a left hemiparesis. Repeated CT scans of the
brain showed expanding ischemic areas parieto-occipital
with secondary bleeding, and the patient finally died.
Thrombosis is the most feared and life-threatening compli-
cation in PNH patients, because after onset, it is frequently
progressive and refractory to anticoagulant therapy [1, 2]. The
mechanism of thrombotic complications in PNH is not com-
pletely understood, but it has mainly been attributed to intra-
vascular hemolysis [1]. Experimental studies show that the free
plasma hemoglobin liberated during hemolysis scavenges nitric
oxide (NO). As a result, NO depletion produces dystonia and
spasm of the smooth muscle, suppresses the anti-inflammatory
effect on the endothelium and promotes platelet activation and
thrombosis [3]. Eculizumab is a monoclonal antibody that
binds complement factor C5, thereby inhibiting complement
activation on erythrocytes and reducing hemolysis. As a result,
eculizumab decreases thrombotic risks in PNH patients [2, 4,
5]. Interestingly, our patient suffered from progressive abdom-
inal and cerebral thrombotic complications without any signs of
intravascular hemolysis. It is also possible that the pathogenesis
of thrombosis in PNH might be caused by other mechanisms
associated to complement activation and not directly related to
hemolysis [1, 6]. We speculate that the mechanism of throm-
bosis could be associated to platelet activation caused by the
absence of CD59 and CD55 on the platelet surface [7, 8].
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Internationally accepted indications for eculizumab treat-
ment include transfusion-dependent hemolysis (four or
more transfusions in 12 months) and PNH-related compli-
cations (i.e., thrombosis or renal failure) regardless of trans-
fusion history [3]. Although no clinical data are available,
eculizumab could be indicated in patients with thrombotic
events in the absence of hemolysis [5, 9, 10].
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Fig. 1 PNH clones at diagnosis (a) and their expansion (b) after
treatment for SAA. Comparison of the PI-deficient clones at diagnosis
of severe aplastic anemia (a) and after triple immunosuppression (b).
Monocytes and granulocytes were gated based on scatter character-
istics and expression of CD33 and CD45. PI deficiency was analyzed
by FLAER and CD14 (monocytes, left panel) or FLAER and CD24
(granulocytes, middle panel). Erythrocytes (right panel) were gated
based on scatter characteristics and PI deficiency was analyzed by
CD59 and CD55. The numbers indicate the percentage of PI-
deficient cells (type III completely lacking GPI-linked proteins) within
the particular lineage. Minor populations of type II cells (partial lacking
GPI-linked proteins) are present as well
1970 Ann Hematol (2012) 91:1969–1970
